C12N 2720/12211
Orthoreovirus
Official title: Orthoreovirus, e.g. mammalian orthoreovirus
C12N2720/12211 (Orthoreovirus) appears on 79 US grants and 103 published applications in this corpus.
Search patents in C12N- Granted patents
- 79
- Published applications
- 103
- Assignees
- 41
- Inventors
- 119
- Latest grant
- 16 Jun 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1991 | 1 | 0 |
| 1992 | 0 | 0 |
| 1993 | 0 | 0 |
| 1994 | 1 | 0 |
| 1995 | 0 | 0 |
| 1996 | 1 | 0 |
| 1997 | 1 | 0 |
| 1998 | 1 | 0 |
| 1999 | 2 | 0 |
| 2000 | 2 | 0 |
| 2001 | 1 | 2 |
| 2002 | 2 | 6 |
| 2003 | 2 | 3 |
| 2004 | 2 | 7 |
| 2005 | 1 | 6 |
| 2006 | 3 | 3 |
| 2007 | 7 | 2 |
| 2008 | 3 | 9 |
| 2009 | 3 | 6 |
| 2010 | 6 | 4 |
| 2011 | 3 | 4 |
| 2012 | 3 | 7 |
| 2013 | 1 | 4 |
| 2014 | 4 | 3 |
| 2015 | 2 | 3 |
| 2016 | 4 | 2 |
| 2017 | 3 | 3 |
| 2018 | 5 | 5 |
| 2019 | 3 | 3 |
| 2020 | 3 | 3 |
| 2021 | 3 | 3 |
| 2022 | 1 | 2 |
| 2023 | 2 | 3 |
| 2024 | 1 | 5 |
| 2025 | 1 | 4 |
| 2026 | 1 | 1 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
- C12N 2720/12232Use of virus as therapeutic agent, other than vaccineIndexing code47
- C12N 2720/12222New viral proteins or individual genes, new structural or functional aspects ofIndexing code22
- C12N 2720/12234Use of virus or viral component as vaccineIndexing code20
- C12N 2720/12251Methods of production or purification of viral materialIndexing code14
- C12N 2720/12221Viruses as suchIndexing code13
- C12N 2720/12261Methods of inactivation or attenuationIndexing code11
- C12N 2720/12241Use of virus, viral particle or viral elements as a vectorIndexing code7
- C12N 2720/12271Demonstrated in vivo effectIndexing code1
Recent patents
- Viral extraction from cell culture16 Jun 2026US 12,655,397 B2National Research Council of Canada
- Oncolytic reovirus13 May 2025US 12,295,977 B2
- Vaccine against infectious bronchitis24 Dec 2024US 12,171,825 B2Zoetis Services LLC
- Vaccines against avian reoviruses14 Nov 2023US 11,813,321 B2Biomune Company
- Fusogenic lipid nanoparticles for target cell-specific production of a therapeutic protein14 Mar 2023US 11,603,543 B2Oisin Biotechnologies, Inc.
- Muns fusion protein capable of forming microspheres and uses thereof27 Aug 2026US 2026/0248905 A1Universidade De Santiago De Compostela
- Viral Extraction from Cell Culture13 Nov 2025US 2025/0346868 A1National Research Council of Canada
- Fusogenic lipid nanoparticles and methods for the manufacture and use thereof for the target cell-specific production of a therapeutic protein and for the treatment of a disease13 Nov 2025US 2025/0346925 A1Oisin Biotechnologies, Inc.
- Vaccine against infectious bronchitis25 Sep 2025US 2025/0295752 A1Zoetis Services LLC
- Compositions and methods for expressing antigens on cell membrane20 Feb 2025US 2025/0057937 A1Zoetis Services LLC
Most cited
By later US patents
- Reovirus for the treatment of cellular proliferative disorders56US 6,136,307 AOncolytics Biotech Inc. · 2000
- Rotavirus nucleocapsid protein VP6 as a carrier in vaccine compositions50US 5,071,651 AUniversity of Saskatchewan · 1991
- Reovirus for the treatment of neoplasia46US 6,110,461 AOncolytics Biotech Inc. · 2000
- Rotavirus nucleocapsid protein VP6 in vaccine compositions42US 5,374,426 AUniversity of Saskatchewan · 1994
- Viral purification methods41US 7,223,585 B2Oncolytics Biotech Inc. · 2007